<DOC>
	<DOCNO>NCT02866331</DOCNO>
	<brief_summary>This study perform reveal safety feasibility combination therapy autologous cord blood mononuclear cell ( CB ) G-CSF well repeat administration G-CSF child cerebral palsy . The evaluation tool follow : ( 1 ) Developmental test ( DDST , PEDI , GMFM , GMFCS , MACS , QUEST ) , ( 2 ) Neurocognitive function test ( WPPSI-IV ) , ( 3 ) Brain MRI-DTI , ( 4 ) Peripheral blood CD34+ cell count , ( 5 ) Neurotrophic factors/anti-inflammatory cytokine .</brief_summary>
	<brief_title>G-CSF Autologous Cord Blood Infusion Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Ages 2 year 10 year time enrollment Nonsevere type cerebral palsy Willing comply study procedures Previous participation within 1 year clinical study stem cell therapy include cord blood , GCSF , erythropoietin Presence chromosomal abnormality Unwillingness participate clinical trial Presence hypersensitivity reaction GCSF Evidence hepatic , renal , cardiac dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>